Xencor, Inc. (NASDAQ:XNCR) Receives $34.88 Average PT from Analysts

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has received a consensus rating of "Buy" from the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $34.88.

Several research analysts recently weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Xencor from $27.00 to $28.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Piper Sandler upgraded shares of Xencor from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. Wells Fargo & Company began coverage on Xencor in a report on Thursday, December 12th. They issued an "overweight" rating and a $37.00 price target for the company. Wedbush restated an "outperform" rating and set a $38.00 price objective on shares of Xencor in a report on Thursday, November 7th. Finally, BMO Capital Markets reiterated an "outperform" rating and set a $34.00 target price (up from $32.00) on shares of Xencor in a research report on Friday, November 8th.

Xencor Price Performance

Shares of XNCR stock traded down $0.27 during trading hours on Monday, hitting $17.25. The company's stock had a trading volume of 690,563 shares, compared to its average volume of 531,669. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $22.57 and a 200-day moving average of $21.01. Xencor has a twelve month low of $15.31 and a twelve month high of $27.24. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -5.39 and a beta of 0.70.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.27. The company had revenue of $10.70 million during the quarter, compared to the consensus estimate of $14.59 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Xencor's revenue was down 81.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.40) earnings per share. As a group, equities research analysts anticipate that Xencor will post -3.68 EPS for the current year.

Insider Transactions at Xencor

In related news, Director Alan Bruce Montgomery sold 1,421 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total transaction of $38,409.63. Following the transaction, the director now directly owns 9,140 shares of the company's stock, valued at approximately $247,054.20. The trade was a 13.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP John R. Desjarlais sold 68,684 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the sale, the vice president now directly owns 200,104 shares of the company's stock, valued at $4,698,441.92. This trade represents a 25.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 136,050 shares of company stock worth $3,277,609 in the last three months. 5.23% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Xencor

Hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. raised its position in shares of Xencor by 147.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company's stock worth $62,748,000 after purchasing an additional 1,858,440 shares during the period. RA Capital Management L.P. bought a new position in Xencor in the 3rd quarter valued at about $11,563,000. RTW Investments LP acquired a new position in shares of Xencor during the third quarter valued at approximately $11,563,000. Braidwell LP bought a new stake in shares of Xencor in the 3rd quarter worth $9,380,000. Finally, Erste Asset Management GmbH acquired a new stake in Xencor in the 3rd quarter valued at about $7,087,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.